Sermorelin Label Updates 2020 to 2026: FDA Status, Compounding Rules, and Safety Data

HealthRX.com

No FDA-approved sermorelin label exists to update

Print or save as PDF

Key numbers

  • 30 micrograms/kgDose given subcutaneously at bedtime in the 1-year pediatric study (a study dose, not a recommendation)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 74%Share of children in the 1-year pediatric study who were good responders at 6 monthsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1 microgram/kgIntravenous dose cited for the old diagnostic test of growth hormone deficiencySource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • Sermorelin approved in the US today / None. Both Geref applications were withdrawn in 2009 [1]
  • The two original approvals / NDA 019863 (0.05 mg ampule, 1990, pituitary diagnostic test) and NDA 020443 (0.5 mg and 1 mg vials, 1997, pediatric growth hormone deficiency) [1]
  • Why it left the market / The maker discontinued Geref in 2008 and asked FDA to withdraw; FDA withdrew both approvals effective June 18, 2009 [1]
  • Withdrawal for safety or effectiveness / No. FDA determined in March 2013 that Geref was not withdrawn for those reasons [1][8]
  • Label revisions 2020 to 2026 / None; there is no approved product [1]
  • FDA safety-risk bulk list (content dated 04/22/2026) / Sermorelin not listed [5]
  • Outsourcing-facility nomination list (updated 03/21/2025) / Sermorelin acetate, category 1 (under evaluation) [6]
  • Sport / WADA prohibits sermorelin at all times under S2.2.4 [9]

Is there a sermorelin label to update in 2026?

No. FDA withdrew approval of NDA 019863 and NDA 020443 effective June 18, 2009, and those two Geref applications are the only sermorelin applications in Drugs@FDA [1][8]. No company holds an approved sermorelin application [1].

The 2020 to 2026 FDA record that mentions sermorelin consists of compounding-list entries, not labeling [5][6][7].

Questions worth asking

Choose the questions you want to keep

What the two Geref approvals covered

Sermorelin was approved twice under the Geref brand.

  • NDA 019863: Geref 0.05 mg per ampule, originally approved December 28, 1990, for evaluating the pituitary's ability to secrete growth hormone [1].
  • NDA 020443: Geref 0.5 mg and 1 mg per vial, originally approved September 26, 1997, for treating idiopathic growth hormone deficiency in children with growth failure [1].

Those were the only approved uses. Geref was not approved for adults, anti-aging, weight loss or athletic performance [1]. Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH), the shortest synthetic peptide with the full biological activity of GHRH, and it is not growth hormone itself [10].

The manufacturer notified FDA of the discontinuation on July 11, 2008 for the 0.05 mg product and December 2, 2008 for the vials, and asked FDA to withdraw the applications [1]. FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness, and Drugs@FDA lists both products as Discontinued with that determination noted [1][8].

What FDA and HHS documents say about sermorelin, 2020 to 2026

Four FDA and HHS documents from that window bear directly on sermorelin [5][6][7][11]. None of them is a label.

  • Safety-risk bulk list (content dated 04/22/2026): sermorelin does not appear, and FDA has published no safety-risk warning about sermorelin as a bulk substance on that page [5]. The same list does carry GHRP-2 and GHRP-6, added September 29, 2023, with concerns that include immunogenicity risk from aggregation and peptide-related impurities [5].
  • Outsourcing-facility nomination list (updated March 21, 2025): sermorelin acetate is in category 1, under evaluation, and carries the list's symbol for bulk substances that are components of FDA-approved drugs [6].
  • State-licensed pharmacy and physician list (updated May 14, 2026): sermorelin appears in no category [7].
  • HHS's October 2026 draft enforcement-discretion policy: six peptides are named, and sermorelin is not one of them [7][11].

Category 1 on the outsourcing list means the nomination is still under evaluation [6].

Safety data: what the studies measured

The clinical study data described here come from studies conducted before the withdrawal.

The largest was a 1-year, open-label, multicenter study of 110 previously untreated prepubertal children with growth hormone deficiency, 86 of whom were evaluable, using 30 micrograms/kg subcutaneously at bedtime [3]. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% of the children were good responders at 6 months [3]. The investigators reported no adverse changes in general biochemical or hormonal analyses, no change in fasting glucose, no excessive generation of IGF-I, and that sermorelin was well tolerated overall [3].

A much smaller physiology study gave 10 healthy older men (mean age 68) 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and compared them with 9 young men (mean age 26) [4]. At the 1 mg dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [4]. It measured hormone levels, not clinical outcomes [4].

An earlier pharmacokinetic study in 30 healthy men aged 19 to 43 found that intravenous GHRH(1-29)-NH2 was rapidly eliminated while growth hormone stayed elevated for about 3 hours; absorption through the nose was low, with bioavailability of 3% to 5% [13].

Adverse-event reports held by FDA cannot supply rates. FDA's own dashboard notes that the reports cannot be used to estimate incidence and that a report does not establish that the drug caused the event [14].

Dosing: there is no current approved dose

There is no current approved dose [1]. Two doses appear in the published studies, and both are study doses rather than recommendations: 30 micrograms/kg once daily subcutaneously at bedtime in the pediatric program [3], and 0.5 mg or 1 mg subcutaneously twice daily for 14 days in the older-men study [4]. For the old diagnostic use, a review reported that hormone responses to intravenous sermorelin 1 microgram/kg appear to be a rapid test for growth hormone deficiency [10].

Sport: WADA prohibits sermorelin

WADA's 2026 Prohibited List names sermorelin in S2.2.4, the growth hormone releasing factors class (GHRH and its analogues, for example CJC-1293, CJC-1295, sermorelin and tesamorelin) [9]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [9]. The 2027 List, in force January 1, 2027, also names it [15].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. In the largest pediatric study, how many children were evaluable?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is sermorelin FDA-approved today?
No. FDA withdrew approval of NDA 019863 and NDA 020443 effective June 18, 2009, and those are the only sermorelin applications in Drugs@FDA [1][8]. Sermorelin sold now is compounded, and compounded drugs are not FDA-approved [2].
Were there any sermorelin label updates between 2020 and 2026?
None. No company holds an approved sermorelin application [1]. The FDA activity in that window that mentions sermorelin concerns bulk substances for compounding [5][6][7].
What does FDA's outsourcing-facility list say about sermorelin acetate?
In the list updated March 21, 2025, sermorelin acetate is in category 1, under evaluation, and is marked as a bulk substance that is a component of FDA-approved drugs [6].
Is sermorelin on FDA's list of bulk substances that may present significant safety risks?
No. Sermorelin is not on that list, whose content is dated 04/22/2026 [5]. The same list includes GHRP-2 and GHRP-6, added September 29, 2023 [5].
What safety data exist for sermorelin?
The 1-year open-label pediatric study of 110 children (86 evaluable) reported no adverse changes in general biochemistry or hormone tests, no change in fasting glucose and no excessive IGF-I rise [3]. The 14-day study in 10 older men measured growth hormone and IGF-I, not clinical outcomes [4].
Is sermorelin banned in sport?
WADA's 2026 Prohibited List names it in S2.2.4, prohibited at all times and in and out of competition, and the 2027 List names it too [9][15].
Show all 15 referencesHide references
  1. Federal Register :: Request Access.
  2. Official web page.
  3. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  4. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. World Anti-Doping Agency.
  10. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  11. Official web page.
  12. Bulk Drug Substances Used in Compounding | FDA.
  13. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
  14. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA.
  15. World Anti-Doping Agency.
Sermorelin label updates: evidence summary chart
Image: HealthRX.com. Full sermorelin label updates guide and sources at healthrx.com/regulatory-sermorelin.